Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study

Antonio Russo, Giusy Blanco, Alessandro Pappalardo, Giusy Blanco, Roberto Bordonaro, Dario Giuffrida, Sergio Castorina, Giuseppe Failla, Daniele Santini, Placida Salice, Carmelo Giannitto Giorgio

Risultato della ricerca: Articlepeer review

61 Citazioni (Scopus)

Abstract

Introduction: The primary tumour type most likely to metastasize to the brain is lung cancer. In heavily pre-treated patients, limited therapeutic option is available and the results of availability therapies reported in literature are disappointing. The present phase II study was designed to assess the efficacy and safety of temozolomide (TMZ) as palliative treatment for brain metastases (BrM) in NSCLC patients pre-treated with WBRT and at least one line of chemotherapy for metastatic brain disease. Material and methods: Temozolomide was administered orally at 150 mg/mq/day for five consecutive days for the first cycle, doses were increased to 200 mg/mq/day for 5 days every 28 days for subsequent cycles if no grade 3/4 haematological toxicity was observed. Eligibility criteria included cytological or histological confirmed NSCLC; BrM, recurrent or progressing after WBRT and at least one line of chemotherapy. A total of 30 consecutive patients entered the study and received the allocated treatment. Results: Three patients (10%) achieved an objective response (OR) of BrM with two complete remission. Stable disease and progressive disease were achieved in 3 (10%) and 24 patients (80%), respectively. A correlation between response to TMZ and sensitivity to the previous first line chemotherapy was reported. Time to progression and overall survival were examined both for responder patients and for all included patients. For long-term survivors, we considered the patients who survived >12 months after the start of TMZ. According to this definition, three patients resulted long-term survivors: 2 with OR and 1 with stable brain disease. No grades 3 or 4 toxicity occurred. The total of treatment-related adverse events were mild or moderate (G1-2) in intensity. No patients discontinued TMZ as a result of treatment-related toxicity. Discussion: The results of the present trial clearly demonstrates that TMZ is active and safe in BrM NSCLC patients previously treated with WBRT and at least one line of chemotherapy. © 2005 Elsevier Ireland Ltd. All rights reserved.
Lingua originaleEnglish
pagine (da-a)247-254
Numero di pagine8
RivistaLung Cancer
Volume50
Stato di pubblicazionePublished - 2005

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2730???
  • ???subjectarea.asjc.2700.2740???
  • ???subjectarea.asjc.1300.1306???

Fingerprint

Entra nei temi di ricerca di 'Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study'. Insieme formano una fingerprint unica.

Cita questo